Non-Small Cell Lung Cancer (NSCLC)
Conditions
Brief summary
Rate of patients without Dose-Limiting Toxicity (DLT).
Detailed description
Presence of adverse events (AEs), including physical examinations, vital signs, electrocardiograms and laboratory clinically significant abnormalities., Objective Response Rate (ORR) (ORR = Complete response (CR) + partial response (PR)), Pathologic response rate (If tumor downsizing and surgical resection become best treatment option)., Proportion of enrolled patients starting RT/CRT within 4 - 5 weeks after durvalumab administration., Proportion of enrolled patients completing the clinical trial.
Interventions
DRUGIMFINZI 50 mg/mL concentrate for solution for infusion.
Sponsors
Instituto Portugues De Oncologia Do Porto Francisco Gentil E.P.E.
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Rate of patients without Dose-Limiting Toxicity (DLT). | — |
Secondary
| Measure | Time frame |
|---|---|
| Presence of adverse events (AEs), including physical examinations, vital signs, electrocardiograms and laboratory clinically significant abnormalities., Objective Response Rate (ORR) (ORR = Complete response (CR) + partial response (PR)), Pathologic response rate (If tumor downsizing and surgical resection become best treatment option)., Proportion of enrolled patients starting RT/CRT within 4 - 5 weeks after durvalumab administration., Proportion of enrolled patients completing the clinical trial. | — |
Countries
Portugal
Outcome results
None listed